Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 1-Year Low at $4.82

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) reached a new 52-week low on Thursday . The company traded as low as $4.82 and last traded at $4.87, with a volume of 115637 shares. The stock had previously closed at $4.91.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on AUPH shares. Jefferies Financial Group lowered their price target on Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating for the company in a report on Friday, February 16th. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, March 1st. Cantor Fitzgerald lowered their price target on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Finally, Royal Bank of Canada lowered their price target on Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating for the company in a report on Friday, February 16th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Aurinia Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Up 3.7 %

The business has a fifty day moving average of $5.49 and a 200 day moving average of $7.27. The company has a market capitalization of $721.64 million, a PE ratio of -9.24 and a beta of 1.36. The company has a current ratio of 5.50, a quick ratio of 4.99 and a debt-to-equity ratio of 0.20.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative return on equity of 20.10%. The firm had revenue of $45.10 million for the quarter, compared to analysts’ expectations of $45.00 million. During the same quarter last year, the business earned ($0.18) earnings per share. The business’s revenue was up 58.8% compared to the same quarter last year. Equities research analysts anticipate that Aurinia Pharmaceuticals Inc. will post -0.06 EPS for the current year.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

A number of hedge funds have recently bought and sold shares of AUPH. Raymond James & Associates acquired a new stake in Aurinia Pharmaceuticals in the 1st quarter valued at about $140,000. BlackRock Inc. raised its position in Aurinia Pharmaceuticals by 0.4% in the 1st quarter. BlackRock Inc. now owns 1,827,416 shares of the biotechnology company’s stock valued at $22,624,000 after purchasing an additional 6,677 shares in the last quarter. Great West Life Assurance Co. Can raised its position in Aurinia Pharmaceuticals by 22.3% in the 1st quarter. Great West Life Assurance Co. Can now owns 6,533 shares of the biotechnology company’s stock valued at $86,000 after purchasing an additional 1,192 shares in the last quarter. Vontobel Holding Ltd. raised its position in Aurinia Pharmaceuticals by 69.9% in the 1st quarter. Vontobel Holding Ltd. now owns 26,000 shares of the biotechnology company’s stock valued at $322,000 after purchasing an additional 10,700 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Aurinia Pharmaceuticals by 26.3% in the 1st quarter. Vanguard Group Inc. now owns 530,059 shares of the biotechnology company’s stock valued at $6,562,000 after purchasing an additional 110,354 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.